Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
EU expands approval of tenofovir disoproxil to include HIV-1, hep B
The European Commission approved tenofovir disoproxil fumarate, combined with other antiretroviral drugs, to treat HIV-1 in patients ages 2 to 17. The drug was also cleared for chronic hepatitis B in patients ages 12 to 17. The approval covers all 27 countries in the European Union.
MedCity News/News release (11/27)
Or we can send an email on your behalf